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Research
Medicinal herbal products have traditionally 
been used as home remedies for treatment 
of many diseases for centuries (Rodriguez-
Fragoso et al. 2008). Although many have 
promising therapeutic potential, in general 
there is a lack of rigorous controlled scien-
tific testing, and little information is available 
regarding appropriate patient use or adverse 
effects. Biosafety and efficacy are major public 
concerns, particularly in developing coun-
tries, which are still establishing bio  safety 
policies. However, the extensive traditional 
uses of non  approved herbal medi  cines, as well 
as environmental exposures, result in a pos-
sible risk of both acute and chronic toxicities. 
Chronic forms of toxicities such as carcinoge-
nicity, mutagenicity, and hepatotoxicity have 
been reported (Pak et al. 2004). In addition, 
some specific patient groups may have more 
of a health risk (e.g., pregnant or nursing 
mothers and the elderly). Herbal medicines 
may also interfere with the efficacy of conven-
tional medicines through herb–drug interac-
tions (Tomlinson et al. 2000). Many herbs 
that have traditionally been reported to have 
estrogen-like activity are potentially abortifa-
cient (Sylvestre et al. 2006), which may affect 
certain groups of individuals. 
Phytoestrogens, plant-derived non  steroidal 
poly  phenolic compounds, are present in soy-
beans, clover, and oilseeds. Isoflavones, lig-
nans, coumestans, resorcylic acid lactones, 
and stilbenes are known phyto  estrogens 
(Knight and Eden 1996). Isoflavones, such 
as genistein, apigenin, and kaemp  ferol, 
have stronger binding affinity for estrogen 
receptor (ER) β than for ERα (Kuiper et al. 
1998). However, the transcriptional activ-
ity of phyto  estrogens such as genistein, daid-
zein, apigenin, naringenin, kaempferol, and 
coumestrol can be mediated by either ERα or 
ERβ (Harris et al. 2005). In addition, the stil-
bene resveratrol, a phyto  estrogen from grapes, 
induced the estrogen-regulated gene pro-
gesterone receptor (PR) in MCF-7 (human 
breast cancer) cells in a dose-dependent man-
ner (Gehm et al. 1997). These estrogen-like 
activities of phyto  estrogens have been demon-
strated to have beneficial roles in prevention 
of several diseases, including cardio  vascular 
diseases, osteoporosis, cancers, and meno-
pausal symptoms (Usui 2006). However, 
phytoestrogen had no significant effect on hot 
flashes in women (Huntley and Ernst 2004). 
Therefore, the search for novel phyto  estrogens 
as an alternative treatment is still a subject of 
high interest for post  menopausal women.
Diarylheptanoids consist of two aro-
matic rings linked by a linear seven-carbon 
aliphatic chain. The first naturally occurring 
diarylheptanoid, curcumin, a yellow dye of 
the Curcuma species, was reported in the 
early 1800s (Keserü and Nógrádi 1995). 
Diarylheptanoids have been reported to have 
a variety of therapeutic actions in vitro such 
as inhibition of platelet aggregation (Doug 
et al. 1998), anti  oxidation (Yao et al. 2007), 
anti  inflammation (Sodsai et al. 2007), and 
antitumor-promoting effects (Chun et al. 
1999; Lee et al. 1998). Because Curcuma 
comosa Roxb., an indigenous medicine, has 
estrogen-like activity (Piyachaturawat et al. 
1995a, 1995b) and has been extensively used 
among menopausal women, it is essential to 
characterize its biological action to avoid any 
risk that may occur from chronic consump-
tion or environmental exposures. Recently, 
diarylheptanoids isolated from C. comosa have 
also been reported to exhibit estrogenic activ-
ity both in vitro (Suksamrarn et al. 2008) and 
in vivo (Winuthayanon et al. 2009) and are 
useful for nutraceutical health promotion and 
hormone replacement therapy. The reported 
high content of diarylheptanoids in C. comosa 
(Suksamrarn et al. 2008) provided this plant 
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Ba c k g r o u n d: Diarylheptanoids isolated from Curcuma comosa Roxb. have been recently identified 
as phyto  estrogens. However, the mechanism underlying their actions has not yet been identified.
oBjectives: We characterized the estrogenic activity of three active naturally occurring diaryl-
heptanoids both in vitro and in vivo.
Me t h o d s: We characterized mechanisms of estrogenic action of the diarylheptanoids (3S)-1,7-
diphenyl-(6E)-6-hepten-3-ol (D1), 1,7-diphenyl-(6E)-6-hepten-3-one (D2), and (3R)-1,7-diphenyl-
(4E,6E)-4,6-heptadien-3-ol (D3) by using a real-time polymerase chain reaction assay, a mammalian 
transfection model, and a uterotrophic assay in mice.
re s u l t s: All diarylheptanoids up-regulated estrogen-responsive genes in estrogen-responsive breast 
cancer cells (MCF-7). In HepG2 cells transfected with estrogen receptor (ER) β or different ERα 
functional receptor mutants and the Vit-ERE-TATA-Luc reporter gene, all diarylheptanoids induced 
transcription through a ligand-dependent human ERα-ERE–driven pathway, which was abolished 
with ICI 182,780 (ER antagonist), whereas only D2 was active with ERβ. An ERα mutant lacking 
the functional AF2 (activation function 2) region was not responsive to 17β-estradiol (E2) or to any 
of the diarylheptanoids, whereas ERα lacking the AF1 domain exhibited wild-type–like activity. D3 
markedly increased uterine weight and proliferation of the uterine epithelium in ovariectomized 
mice, whereas D1 and D2 were inactive. D3, like E2, up-regulated lactoferrin (Ltf) gene expression. 
The responses to D3 in the uterus were inhibited by ICI 182,780. In addition, D3 stimulated both 
classical (Aqp5) and non  classical (Cdkn1a) ER-mediated gene regulation.
co n c l u s i o n s: The results suggest that the D3 diarylheptanoid is an agonist for ER both in vitro 
and in vivo, and its biological action is ERα selective, specifically requiring AF2 function, and 
involves direct binding via ER as well as ERE-independent gene regulation.
key w o r d s : Curcuma comosa, diarylheptanoid, ER dependent, ERE dependent, ERE indepen-
dent, estrogen-regulated genes, uterotrophic activity Environ Health Perspect 117:1155–1161 
(2009).  doi:10.1289/ehp.0900613 available via http://dx.doi.org/ [Online 23 March 2009]Winuthayanon et al.
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species as an attractive source of novel phyto-
estrogens. However, the precise mechanisms of 
the estrogenic action of diaryl  heptanoids have 
not yet been identified. The diaryl  heptanoids 
(3S)-1,7-diphenyl-(6E)-6-hepten-3-ol (D1), 
1,7-diphenyl-(6E)-6-hepten-3-one (D2), and 
(3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-
-ol (D3; Figure 1), the major components of 
C. comosa, exhibited high estrogenic activ-
ity (Suksamrarn et al. 2008). In the present 
study we aimed to characterize the estrogenic 
activity of these potent naturally occurring 
diarylheptanoids in vivo and determine their 
mechanism of action on ERs in vitro by using 
well-characterized and appropriate experimen-
tal model systems.
Materials and Methods
Chemicals and compounds. We obtained 
DNA restriction and modification enzymes 
from New England Biolabs Inc. (Beverly, 
MA, USA) and polymerase chain reaction 
(PCR) reagents from Promega (Madison, 
WI, USA). We purchased 17β-estradiol (E2), 
DMSO, flutamide, and sesame oil from Sigma 
(St. Louis, MO, USA). All chemicals were 
dissolved in ethanol (EtOH) unless other-
wise indicated. ICI 182,780 (ICI) was pur-
chased from Tocris Bioscience (Ellisville, MS, 
USA) and dissolved in DMSO. The diaryl-
heptanoids used in this study (D1, D2, and 
D3) were isolated from C. comosa as described 
previously by Suksamrarn et al. (2008). We 
checked the purity of these compounds by 
thin-layer chromatography and nuclear mag-
netic resonance spectroscopy.
Plasmids. The mammalian expression 
plasmids for human ERα (hERα) and hERβ 
(pcDNA3-hERα and pcDNA3-hERβ) have 
been described previously (Hall and Korach 
2002). The expression plasmids for mouse 
ERα wild-type (pcDNA3-mERαWT) and 
AF1 domain deleted mouse ERα (mERKOE1; 
pcDNA3-mERKOE1) have been previously 
described (Couse et al. 1995). To make the 
pcDNA3-mAF2ER plasmid, the leucine 
residues corresponding to amino acids 543 
and 544 of mouse ERα were replaced with 
alanine by using QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, 
USA) according to the manufacturer’s instruc-
tions. We used the pcDNA3-mERαWT 
plasmid as a template and reacted it with the 
oligo  nucleotide primers: 5´-GTG CCC CTC 
TAT GAC GCG GCT CTA GAG ATG 
TTG GAT GCC CAC-3´ and 5´-GTG GGC 
ATC CAA CAT CTC TAG CTC CGC GTC 
ATA GAG GGG CAC-3´. The mutated clone 
was confirmed by sequencing. The 3×-Vit-
ERE-TATA-Luc plasmid was a gift from D.P. 
McDonnell (Duke University Medical Center, 
Durham, NC, USA).
Uterine bioassay in adult wild-type 
(WT) ovariectomized mice. Animals were 
handled according to National Institute of 
Environmental Health Sciences (NIEHS) 
Animal Care and Use Committee guidelines 
and in compliance with an NIEHS-approved 
animal protocol; all animals were treated 
humanely and with regard for alleviation 
of suffering. Adult female C57BL6J mice, 
approximately 10 weeks of age, were either 
purchased from Charles River Laboratories 
(Raleigh, NC, USA) or generated at the 
NIEHS. All mice were ovariectomized (OVX) 
and housed for 10–14 days to eliminate 
endogenous ovarian steroids before the study. 
Animals were treated with sesame oil (vehicle), 
2.5 mg diaryl  heptanoids (D1, D2, or D3), or 
0.25 µg E2 in 100 µL sesame oil (body weight, 
~ 25 g per mouse) by subcutaneous adminis-
tration. Some animals were treated with 45 µg 
ICI or 2 mg flutamide [androgen receptor 
(AR) antagonist] dissolved in 50 µL DMSO 
injected intra  peritoneally 30 min before E2 
or diaryl  heptanoid injection. Animals were 
treated every 24 hr for 3 consecutive days. 
Animals were sacrificed 24 hr after the last 
injection by using CO2 asphyxiation, and the 
uteri were collected, blotted, and weighed. 
A portion of each uterus was fixed in 10% 
formalin, embedded in paraffin, and cross-
sectioned. We detected Ki67 as previously 
described (Hewitt et al. 2006). The remaining 
uterine samples were snap frozen in liquid 
nitrogen for later RNA isolation using Trizol 
reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. 
Nonclassical ERE-independent gene analy-
sis in knock-in/knockout (KI/KO) mice. Adult 
female C57BL6J ERα knockout (αERKO) 
mice (Lubahn et al. 1993) were generated at 
Taconic Farms (Germantown, NY, USA). 
The KI/KO (heterozygous male non  classical 
ER knock-in NERKI(–/+) × female αER(–/+)) 
mice were generated at Charles River 
(Wilmington, MA, USA) as described previ-
ously (Jakacka et al. 2002). All mice used were 
ovariectomized and housed for 10–14 days. 
Wild-type (WT), αERKO, and KI/KO OVX 
mice were treated with sesame oil (vehicle), 
2.5 mg D3 (the most potent among the three 
diaryl  heptanoids on uterotrophic action), or 
0.25 µg E2 in 100 µL sesame oil, by subcuta-
neous administration. Animals were sacrificed 
2 hr after treatment, and uteri were collected 
and snap frozen for later RNA isolation.
Cell culture conditions. MCF-7 human 
breast cancer cells, which express ERs, 
were grown in phenol red–free Dulbecco’s 
modified Eagle medium/Nutrient Mix F12 
(DMEM/F12) media containing 10% fetal 
bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA, USA), 100 U/mL penicil-
lin, and 100 µg/mL streptomycin. HepG2 
(human hepatocellular carcinoma) cells, which 
do not express ERs, were grown in phenol 
Figure 1. Structure of the  diarylheptanoids 
(3S)-1,7-diphenyl-(6E)-6-hepten-3-ol  (D1), 
1,7-diphenyl-(6E)-6-hepten-3-one (D2), and (3R)-1,7-
diphenyl-(4E,6E)-4,6-heptadien-3-ol (D3), purified 
compounds isolated from rhizome (Suksamrarn 
et al. 2008).
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Table 1. Human and mouse primers.
Gene symbol (complete name; GenBank accession number)  Sequence (5´ → 3´)
Aqp5 (aquaporin 5; NM_009701.4)  F: ACAGGGCCTCTTTGGAATTAGG
  R: TGAGCTTGCACTGCCTTCAC
B2M (beta-2-microglobulin; NM_004048.2)  F: TGCTCGCGCTACTCTCTCTTT
  R: TCTGCTGGATGACGTGAGTAAAC
Cdkn1a (cyclin-dependent kinase inhibitor 1A; NM_007669.4)   F: CAGCGACCATGTCCAATCC
  R: CGAAGAGACAACGGCACACTT
CTSD (cathepsin D; NM_001909.3)  F: ACTGCTGGACATCGCTTGCT
  R: TGTCAAACGAGGTACCATTCTTCA
Ltf (lactotransferrin; NM_008522.3)  F: CAGCAGGATGTGATAGCCACAA
  R: CACTGATCACACTTGCGCTTCT
MYC (v-myc myelocytomatosis viral oncogene homolog; NM_002467.3)  F: TGCCGCATCCACGAAACT
  R: GTCCTTGCTCGGGTGTTGTAAG
PGR (progesterone receptor; NM_000926.4)  F: GACGTGGAGGGCGCATAT
  R: AGCAGTCCGCTGTCCTTTTCT
Rpl7 (ribosomal protein L7; NM_011291.4)  F: AGCTGGCCTTTGTCATCAGAA
  R: GACGAAGGAGCTGCAGAACCT
TFF1 (trefoil factor 1;pS2 NM_003225.2)  F: GCCCTCCCAGTGTGCAAATA
  R: CTGGAGGGACGTCGATGGTA
Abbreviations: F, forward; R, reverse. The primer sequences were created using Applied Biosystems Primer Express 
Software version 2.0. All gene names and accession number were obtained from GenBank (National Center for 
Biotechnology Information 2009). Diarylheptanoids: ER-dependent action
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red–free minimum essential medium (MEM) 
containing 2 mM l-glutamine, 10% FBS, 
100 U/mL penicillin, and 100 µg/mL strep-
tomycin. We purchased culture reagents from 
Invitrogen unless otherwise indicated. 
MCF-7 cell treatment and RNA isolation. 
MCF-7 cells were plated in six-well plates at 
a density of 1 × 106 cells/well overnight in 
DMEM/F12 containing 10% FBS. Cells were 
then washed twice with phosphate-buffered 
saline (PBS), and 2 mL DMEM/F12 con-
taining 10% dextran coated-charcoal FBS 
[stripped FBS (SFBS; Hyclone, South Logan, 
UT, USA] was added into each well. After 
24 hr, cells were treated with EtOH (vehicle), 
1 nM E2, or various concentrations of diaryl-
heptanoids in the presence or absence of 1 µM 
ICI for 24 hr. We isolated the total RNA 
from MCF-7 cells using the RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the 
manufacturer’s protocol. We then reverse tran-
scribed 2 µg total RNA using the SuperScript 
First-Strand Synthesis System (Invitrogen). 
Real-Time PCR. We synthesized cDNA 
from MCF-7 cells and mouse uteri and 
obtained cycle time (Ct) values by real-time 
PCR with SYBR Green I dye using the ABI 
PRISM 7900 Sequence Detection System and 
analysis software (Applied Biosystems, Foster 
City, CA, USA) as previously described (Hewitt 
et al. 2005). Primer sequences were created 
using Applied Biosystems Primer Express 
Software (version 2.0) or were purchased from 
Sigma-Genosis (St. Louis, MO, USA); the 
sequences for primers are shown in Table 1. 
We determined the expression ratios relative 
to vehicle control and normalized them to a 
ribosomal protein L7 gene (Rpl7) for uterine 
samples and beta-2-micro  globulin gene (B2M) 
for samples from MCF-7 cells by quantification 
of cDNA according to the mathematical model 
described by Pfaffl (2001).
Transient transfection and luciferase assay 
in HepG2 cells. HepG2 cells were plated in 
24-well plates at a density of 2 × 105 cells/well 
in MEM containing 10% SFBS and incu-
bated overnight. Cells were washed twice with 
PBS, and then 500 µL MEM with 10% SFBS 
was added to each well. Cells were transfected 
for 6 hr with 0.1 µg/µL pcDNA3-hERα, 
pcDNA3- hERβ, pcDNA3-mERαWT, pcD-
NA3-mERKOE1, pcDNA3-mAF2ER, 3×-Vit-
ERE-TATA-Luc, or pRL-TK (constitutively 
active Renilla reporter plasmid; Promega) by 
using FuGENE6 transfection reagent (Roche 
Applied Science, Indianapolis, IN, USA). 
Afterward, we treated cells for 20 hr with 1 nM 
E2 or various concentrations of diaryl  heptanoids 
in the presence or absence of 1 µM ICI. We 
then assayed HepG2 cells for luciferase activity 
using the Dual-Luciferase reporter assay sys-
tem (Promega) and an LMAXII luminometer 
(Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis. We assessed data sets 
for statistical significance (p < 0.05) using Jmp 
Software, version 5.0 (SAS Institute Inc., Cary, 
NC, USA). All data were assessed for statisti-
cally significant differences via a one-way anal-
ysis of variance followed by the Tukey-Kramer 
post hoc test.
Results
ER-Dependent Estrogenic Activity 
in Vitro
Diarylheptanoids stimulate estrogen-regulated 
genes in MCF-7 cells. To elucidate the specific-
ity of the estrogenic response, we assessed the 
activity of diarylheptanoid on the expression 
of estrogen-regulated genes: TFF1 (or pS2) 
(May and Westley 1997), progesterone recep-
tor (PGR) (Soto et al. 1995), MYC (Dubik 
et al. 1987), and cathepsin D (CTSD) (Westley 
and May 1987), which are known estrogen-
inducible genes in MCF-7 cells. As shown 
in Figure 2, we determined a dose–response 
effect in which 50 µM of D1, D2, and D3 
significantly increased the mRNA expression 
of TFF1, MYC, and CTSD to a level compa-
rable to that induced by 1 nM E2. However, 
at a dose of 50 µM, D2 and D3 significantly 
increased PGR expression, but D1 was weak 
and its effect was not statistically different from 
that of EtOH. The responses of all diaryl-
heptanoids (D1, D2, and D3) and E2 were 
fully inhibited in the presence of 1 µM ICI.
Diarylheptanoids require the AF2 (activa-
tion function 2) region of ER for transactiva-
tion function. We examined the molecular 
mechanism of ER-dependent gene regulation 
by diaryl  heptanoid. HepG2 cells that do not 
express ERs were transiently transfected with 
plasmids containing either hERα or hERβ 
and an estrogen-responsive element (ERE)-
fused luciferase reporter plasmid (3×-Vit-
ERE-TATA-Luc) (Figure 3). In the presence 
Figure 2. Endogenous gene expression in MCF-7 cells treated with EtOH (vehicle), 1 nM E2, or 1, 10, 20, or 50 µM diarylheptanoid (D1, D2, or D3) in the presence or 
absence of 1 µM ICI for 24 hr. Fold activation of TFF1 (A), PGR (B), MYC (C), and CTSD (D) compared with EtOH. Each value represents the average increase above 
EtOH obtained from three independent experiments performed in duplicate. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with EtOH.
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of hERα, diarylheptanoids (D1, D2, and D3) 
stimulated ERE-mediated luciferase activity 
in a dose-dependent manner, with the maxi-
mum relative luciferase activity at a dose of 
50 µM comparable to the activity of 1 nM 
E2 (Figure 3A). Coincubation with 1 µM ICI 
inhibited the transactivation of 3×-Vit-ERE-
TATA-luc plasmid by diaryl  heptanoids and 
E2. In the presence of hERβ, only 50 µM 
D2 or 1 nM E2 significantly stimulated the 
luciferase activity (Figure 3B). However, 
neither D1 nor D3 at any concentration 
stimulated the ERβ-mediated luciferase trans-
activation, suggesting that D1 and D3 can 
activate their estrogenic actions through ERα 
but not through ERβ, whereas D2 can exert 
its transcriptional activity through either ERα 
or ERβ.
To evaluate the effect of diarylheptanoids 
on specific functional domains of ER, we 
cotransfected plasmids expressing mutated 
ER with ERE-dependent luciferase reporters 
(3×-Vit-ERE-TATA-Luc) in HepG2 cells. In 
the presence of AF1 domain-deleted mouse 
ERα (mERKOE1) plasmid, 50 µM diaryl-
heptanoids (D1, D2, and D3) and 1 nM E2 sig-
nificantly stimulated ERE-dependent luciferase 
activity in a manner similar to that of WT ERα 
(mERαWT) (Figure 4). Unlike the AF1 muta-
tion, diarylheptanoids (D1, D2, and D3) and 
E2 both failed to stimulate ERE-dependent 
luciferase activity of the mouse ERα contain-
ing two-point mutations in its AF2 domain 
(mAF2ER). However, 1 µM ICI significantly 
stimulated the ERE-mediated luciferase activity 
of the mAF2ERα in a manner described previ-
ously by Mahfoudi et al. (1995).
ER-Dependent Estrogenic Activity 
in Vivo
Estrogenic activity of diarylheptanoids was 
also evaluated in vivo using a 3-day uterine 
bio  assay in mice. Uterine weights were signifi-
cantly increased, approxi  mately 1.8-fold, by 
2.5 mg D3 compared with a 4.6-fold increase 
seen with 0.25 µg E2, the positive control 
(Figure 5A). However, D1 and D2 had no 
effect on uterine weight. Treatment with 
45 µg ICI essentially abolished the increase 
in uterine weight in both D3- and E2-treated 
groups. To test whether the uterotrophic 
activity of D3 may be mediated through the 
AR (Hewitt et al. 2006), we cotreated mice 
with 2 mg flutamide (AR antagonist) and D3. 
The results showed that flutamide did not 
significantly alter the action of D3 in mouse 
uterus. Expression of the uterine estrogen-
  inducible gene lactoferrin (Ltf) was increased 
by D3 and E2 (6.8- and 96.6-fold, respec-
tively). ICI inhibited the D3- or E2-mediated 
induction of Ltf (Figure 5B). Flutamide did 
not alter the D3-mediated change in Ltf 
expression; the level of expression was approx-
imately 9.9-fold.
To evaluate the effect of the compounds 
on uterine epithelial proliferation, we ana-
lyzed Ki67, a marker for proliferation (Gerdes 
et al. 1984), by immunohistochemistry. Ki67 
was increased in uterine epithelia of mice 
treated with 2.5 mg D3 and 0.25 µg E2, as 
well as those cotreated with 2.5 mg D3 and 
2 mg flutamide, compared with vehicle con-
trol (Figure 6). We detected no staining in 
those mice that received D1, D2, and ICI.
Figure 3. Relative luciferase activity in HepG2 cells transfected with hERα (A), hERβ (B), and 3 ×-Vit-ERE-TATA-Luc plasmids that we treated with EtOH (vehicle), 
1 nM E2, or 1, 10, 20, 50 µM diarylheptanoid (D1, D2, or D3) in the presence or absence of 1 µM ICI. Each value was obtained from three independent experiments 
performed in triplicate. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with EtOH.
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Classical and ERE-independent gene 
activation in vivo. To elucidate whether the 
uterotrophic activity of D3, the most potent 
estrogenic compound among the diaryl-
heptanoid analogues in the uterus, can use 
the non  classical ERE-independent path-
way, we compared gene response in KI/KO, 
αERKO, and WT OVX mice because KI/
KO mice selectively use the ERE-independent 
mechanism of ER (O’Brien et al. 2006). 
We determined the expression of an ERE-
dependent gene (aquaporin 5; Aqp5) and 
an ERE-independent gene (Cdkn1a or p21) 
(O’Brien et al. 2006). Treatment for 2 hr 
with 2.5 mg D3 or 0.25 µg E2 did not alter 
the expression of Aqp5 in either KI/KO or 
αERKO mice (Figure 7A). However, D3 
and E2 markedly increased the expression 
of Aqp5 in WT mice compared with vehicle 
control. In addition, the results showed that 
Cdkn1a was up-regulated similarly in both 
WT and KI/KO mice by D3 or E2 treat-
ment (Figure 7B). These findings suggest 
that diaryl  heptanoid (D3) stimulates gene 
expression in the uterus through both classical 
and tethered ERα-mediated pathways.
Discussion
In this study we characterized the estrogenic 
activity of diarylheptanoids, naturally occur-
ring compounds from C. comosa, in estab-
lished in vitro and in vivo model systems. 
Diarylheptanoids (D1, D2, and D3) stimulated 
several endogenous estrogen-regulated genes 
in MCF-7 cells in an ER-dependent manner. 
Transcriptional activation of a reporter gene 
required a functional AF2 region of the ER 
protein. Moreover, we demon  strated that only 
the D3 compound exerted ER-dependent 
utero  trophic activity in WT OVX mice. 
Additionally, the estrogenic activity of D3 in 
the uterus was mediated through both classi-
cal and non  classical ERE-independent mech-
anisms. To our knowledge, this is the first 
study showing the molecular mechanism and 
selectivity of these diarylheptanoids as novel 
phyto  estrogens. 
We explored the specificity of diaryl-
heptanoids on several known estrogen-regulated 
endogenous genes in MCF-7 cells, a well- 
established estrogen-sensitive cell model used 
to assay the estrogenicity of putative estro-
genic chemicals (Jorgensen et al. 2000). E2 has 
been shown to up-regulate TFF1 (May and 
Westley 1997), PGR (Nardulli et al. 1988), 
MYC (Dubik et al. 1987), and CTSD (Westley 
and May 1987) in breast tissues. These genes 
contain non  consensus ERE sequences on their 
promoters (Berry et al. 1989; Dubik and Shiu 
1992; Petz and Nardulli 2000; Wang et al. 
1997). In the present study, D1, D2, and 
D3 induced the expression of almost all these 
genes, whereas D1 weakly increased the expres-
sion of PGR. The effects were ER dependent 
because they were inhibited by ICI. Therefore, 
diaryl  heptanoids induced these E2-regulated 
endogenous genes in MCF-7 cells in a manner 
similar to other reported estrogen agonists.
Both ERα and ERβ are able to bind 
to a number of structurally diverse com-
pounds (Kuiper et al. 1998); here, using an 
ERE-driven luciferase assay to assess diaryl-
heptanoid-induced transactivation, we dem-
onstrated that the diarylheptanoids D1 and 
D3 induced ERE-dependent luciferase activ-
ity only in the presence of hERα, and not 
hERβ. Based on previous reports of ERβ 
selectivity for xeno  estrogen binding (Kuiper 
et al. 1998), it was surprising that D1 and D3 
stimulated no activity with ERβ. The differ-
ence may be that our study is a direct func-
tional assessment of receptor-mediated actions 
versus a ligand-binding activity, which does 
not necessary reflect biological activity. Our 
study indicated that D1 and D3 had selectiv-
ity toward hERα/ERE-driven transcription. 
However, D2 had no selectivity for a specific 
ER form because D2 mediated transcription 
Figure 6. Ki67 immunohistochemistry. Cross-sectional uterine tissues from adult OVX mice treated 3 con-
secutive days with sesame oil (vehicle; A), 0.25 µg E2 (B), 45 µg ICI + E2 (C), 2.5 mg D1 (D), 2.5 mg D2 (E), 2.5 
mg D3 (F), 45 µg ICI + 2.5 mg D3 (G), and 2 mg flutamide + 2.5 mg D3 (H). Tissues are stained with an anti-
body to the proliferative marker Ki67. Bar = 40 µm. Winuthayanon et al.
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through either ERα or ERβ. This may reflect 
subtle differences in the ligand binding pocket 
of ERα and ERβ for D1 and D3. 
Transcriptional activity of estrogenic com-
pounds depends on the cellular and promoter 
contexts that are mediated by two different 
activation functions of the ER: AF1 and AF2 
(Tzukerman et al. 1994). In most cases, AF1 
works synergistically with AF2 to activate tran-
scription through coregulatory factors such as 
TIF2 (p160 coactivator family) (Benecke et al. 
2000). We found that the AF1 region of ER 
was dispensable for transcriptional activity of 
all three diaryl  heptanoids (D1, D2, and D3) 
as well as E2 in the HepG2 cell model. Several 
phosphorylation sites have been identified in 
the A/B domain/AF1 region of the N-terminus 
of ERα (Lannigan 2003). Therefore, because 
this region is not required for activity, phos-
phorylation of the A/B domain of ER may 
not play a role in estrogenic activity of E2 or 
diarylheptanoids in HepG2 cells. The role of 
AF2 in ER activity is also cell-type specific 
(Tzukerman et al. 1994). In contrast, partial 
deletion of various ER regions has indicated 
that the AF2 region of ER is required for hor-
mone-dependent transcription (Danielian et al. 
1992). Here, we constructed an ER with point 
mutations at L543A/L544A that resides in the 
AF2 region on helix 12; because helix 12 of the 
ligand-binding domain forms part of a hydro-
phobic cavity of the receptor that is crucial for 
E2 agonist binding (Brzozowski et al. 1997), 
this mutation dampened the transcriptional 
activity of E2 as well as the diaryl  heptanoids. 
Therefore, these hydrophobic amino acids 
(L543 and L544) would appear to be involved 
in the inter  action between diaryl  heptanoids and 
the ER, as is also seen with other ER agonists. 
We therefore surmise that diaryl  heptanoids 
behave more like agonists than antagonists, as 
shown by these responses that are similar to 
those of E2.
The classical uterine bioassay, which 
meas  ures any increase in uterine weight that 
results from administration of a test substance, 
is a useful tool for determining estrogenic-
ity (Owens and Ashby 2002). In the present 
study, D3 caused a marked increase in uterine 
weight, although the increase was less than that 
of E2. Interestingly, the uterotrophic response 
to D3 proved to be ER dependent because 
it was essentially inhibited by ICI, a specific 
ER antagonist, and we observed no activ-
ity in αERKO mice. In addition, AR is also 
expressed in uterine tissues, and androgen-spe-
cific ligands, such as 5α-dihydrotestosterone 
or synthetic androgen, can increase uterine 
weight. Flutamide, an AR antagonist, inhibits 
the response (Hewitt et al. 2006). However, 
the uterine action of diarylheptanoid was not 
mediated through AR because flutamide did 
not inhibit the increased uterine weight. These 
findings confirmed that the estrogenic activity 
of diaryl  heptanoid was not through the AR.
The stimulatory effect of D3 on the prolif-
eration of uterine epithelium was further sup-
ported by anti-Ki67 immunohisto  chemistry 
staining, which detects a nuclear antigen pres-
ent only in proliferating cells (S, G2, and M 
phase) (Gerdes et al. 1984). We found posi-
tive staining of anti-Ki67 within the uterine 
epithelium in mice treated with E2, D3, or 
D3 together with flutamide. Therefore, D3 
exhibited a proliferative effect similar to E2 on 
mouse uterine epithelial cells.
Several studies have shown that Ltf, an 
iron-binding glyco  protein (Teng 2002), is an 
E2-inducible gene in uterine epithelium in 
mice (Hewitt et al. 2003), rats (Jefferson et al. 
2000), monkeys, and humans (Teng et al. 
2002). Ltf is also present in most exocrine 
secretions and in the secondary granules of 
polymorphonuclear leucocytes (Walmer et al. 
1992). The expression of mouse Ltf in the 
genital tract is correlated with rising serum 
estradiol concentration because the protein has 
been detected at early and late estrous during 
natural estrous cycle (Walmer et al. 1992). 
Moreover, an ERE is located on the promoter 
of the Ltf gene (Ray et al. 2006). In the pres-
ent study, the D3–up-regulated Ltf expression 
was similar to that of estrogen but less robust. 
In addition, the Ltf expression pattern corre-
lated well with the increase in uterine weight. 
Use of selective antagonists showed the effect 
of D3 on Ltf expression was also ER depen-
dent, not mediated through AR. Although D1 
and D2 showed estrogenic activity in in vitro 
experiments that was similar to D3, neither 
D1 nor D2 was effective in stimulating uterine 
response. This may be due to metabolic inacti-
vation of D1 and D2 in the whole mouse. 
Therefore, estrogenicity of compounds should 
be evaluated in both in vivo and in vitro mod-
els to allow the full assessment and appreci-
ation of the exact biological responses that 
could be expected with human exposures.
We then evaluated in more detail the dif-
ferent potential mechanisms of action of D3 
through both classical and non  classical ER 
pathways. In the classical pathway, E2–ER 
binds directly to ERE DNA motifs in genes 
(ERE dependent), whereas ERα can inter-
act with other DNA-binding transcription 
factors by protein–protein interaction (ERE 
independent) (Hall et al. 2001). The KI/KO 
mice were previously used to elucidate the 
in vivo ERE-independent signaling of estrogen 
because they lacked any ERE binding activ-
ity due to a DNA binding domain mutation 
of ERα (O’Brien et al. 2006). Increase in 
Aqp5 transcript required the ERE-mediated 
pathway, whereas increase in Cdkn1a (p21) 
could be regulated by the ERE-independent 
mechanism (O’Brien et al. 2006). Moreover, 
the ERE element in the 5´ region of Aqp5 
was directly regulated by E2–ERα (Kobayashi 
et al. 2006). Herein, we demonstrated that 
Aqp5, one of the important genes for fluid 
absorption, was up-regulated by D3 and E2 
only in WT mice. We also demonstrated D3 
was able to up-regulate Cdkn1a both in WT 
and KI/KO, which implied that D3 is able to 
exert estrogenic activity through either classi-
cal or ERE-independent mechanisms in vivo. 
Aqp5 and Cdkn1a were not up-regulated by 
D3 and E2 in αERKO mice, indicating the 
ER-dependence of these genes’ activation.
In conclusion, the present study suggests 
that diaryl  heptanoids (D1, D2, and D3) 
exhibit estrogenic properties selectively through 
ERα, particularly requiring AF2. Moreover, 
the estrogenic activity of D3 can involve direct 
DNA binding or ERE-independent gene regu-
lation both in vitro and in vivo. This is the first 
report on the molecular mechanism underly-
ing the action of diarylheptanoid, the major 
compound in the environmental phytoestro-
gen C. comosa, thereby confirming estrogenic 
activity, which provides evidence and expla-
nation for therapeutic and exposure effects 
and potential further development. Because 
the in vivo actions of diarylheptanoid (D3) 
appear to be selective for ERα, the potential 
target tissues that can be affected include any 
tissues that predominantly express ERα, not 
merely the reproductive system. Evidence of 
primary physiologic roles and actions for ERα 
is exemplified from studies involving the ER 
Figure 7. Effect of D3 on the classical (ERE-mediated) and non  classical genes in mouse uteri. Aqp5 (A), 
and Cdkn1a (B) in mouse uteri from adult WT, αERKO, and KI/KO OVX mice treated for 2 hr with vehicle 
(sesame oil), 0.25 µg E2, or 2.5 mg D3. Data represent the mean ± SE increase above the vehicle group, with 
expression ratios normalized to Rpl7 by real-time reverse transcriptase PCR (n = 3–7 animals/group). 
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knockout mouse models (Couse and Korach 
1999) and a patient with an ERα inactivation 
mutation (Smith et al. 2008).
Another issue of concern is that plants such 
as Curcuma longa (turmeric), which contain 
diaryl  heptanoids, have been used extensively 
for cancer chemoprevention. Surprisingly, 
none of the diaryl  heptanoid cancer prevention 
studies have evaluated effects in the reproduc-
tive system. Our study provides evidence that 
diaryl  heptanoids exhibit sex-steroid (estrogen)-
like activity in vivo. Additionally, we report 
in vitro evaluation of possible mecha  nisms of 
action. Our findings may evoke public interest 
concerning any hormonal disturbance result-
ing from use or exposure to such plant-de-
rived products and add further evidence to 
the investigation of the sources and chemical 
nature of phyto  estrogens.
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